Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 2/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.51 |
| ▸ | CDC25B | P30305 | 8/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.51 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.51 |
| ▸ | GJA1 | P17302 | 1/20 | 0.49 |
| ▸ | TACR2 | P21452 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9853868 | 1.00 | GJB2 (0.58) | GJB2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL9853872 | 1.00 | GJB2 (0.58) | GJB2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL14414817 | 0.93 | GJB2 (0.56) | GJB2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL5466098 | 0.93 | GJB2 (0.56) | GJB2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL24479039 | 0.92 | SLC6A2 (0.53) | GJB2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL10865849 | 0.92 | SLC6A2 (0.53) | GJB2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL18671703 | 0.91 | SSTR1 (0.58) | GJB2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL10609599 | 0.91 | SSTR1 (0.58) | GJB2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL22858228 | 0.91 | SSTR1 (0.58) | GJB2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL22659920 | 0.91 | SSTR1 (0.58) | GJB2NT5EPTPN1CDC25BPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058888-A1 | Methods for synthesis of alpha-d-gal (1~>3) gal-containing oligosaccharides | ALCHEMIA PTY LTD. (AU) | 2004-03-25 | — | — | US | disclosed |
| EP-1257558-A1 | METHODS FOR SYNTHESIS OF ALPHA-D-GAL (1- 3) GAL-CONTAINING OLIGOSACCHARIDES | Alchemia Pty Ltd (AU) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001051499-A1 | METHODS FOR SYNTHESIS OF α-D-GAL (1→3) GAL-CONTAINING OLIGOSACCHARIDES | ALCHEMIA PTY LTD (AU) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058888-A1 | Methods for synthesis of alpha-d-gal (1~>3) gal-containing oligosaccharides | B4GALT1, B3GAT3, FUT5 | GJB2 4343/4885NT5E 3592/4885PTPN1 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.